---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-030816"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2025-10-10T23:59:59+00:00"
generated_at: "2026-05-17T04:04:46.366398+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences reports 94% PVI success at 3 months in nPulse cardiac study

## Summary
- All (100%) posterior box isolations acutely successful in high-dose cohort; 94% PVI success per vein at ~3 months.
- Average total ablation time of 50 seconds with 13 applications; no esophageal or phrenic nerve damage reported.
- No ablation-related severe or major adverse events in 44 treated patients across three European sites.
- CEO confirms on track to initiate IDE study this year for nPulse Cardiac Surgical System.

## SEC filing metadata
- accession: 0001437749-25-030816
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2025-10-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774925030816/0001437749-25-030816-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774925030816/plse20251009_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-030816
- JSON: https://secwatch.observer/filing/0001437749-25-030816.json
- Plain text: https://secwatch.observer/filing/0001437749-25-030816.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.